➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Mallinckrodt
Express Scripts
McKinsey
Dow

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 7,867,492

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,867,492
Title:Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
Abstract: Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in hematopoietic malignancy cells, and determined to be associated with growth and proliferation of the malignancy cells. Accordingly, methods are provided for treating a hematopoietic cell malignancy associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a hematopoietic cell malignancy to treatment with an Hh pathway antagonist.
Inventor(s): Beachy; Philip Arden (Stanford, CA), Kim; Jynho (Palo Alto, CA)
Assignee: The John Hopkins University (Baltimore, MD) The Board Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Application Number:12/249,860
Patent Claims:see list of patent claims

Details for Patent 7,867,492

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial The John Hopkins University (Baltimore, MD) The Board Trustees of the Leland Stanford Junior University (Palo Alto, CA) 2027-10-12 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial The John Hopkins University (Baltimore, MD) The Board Trustees of the Leland Stanford Junior University (Palo Alto, CA) 2027-10-12 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial The John Hopkins University (Baltimore, MD) The Board Trustees of the Leland Stanford Junior University (Palo Alto, CA) 2027-10-12 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial The John Hopkins University (Baltimore, MD) The Board Trustees of the Leland Stanford Junior University (Palo Alto, CA) 2027-10-12 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial The John Hopkins University (Baltimore, MD) The Board Trustees of the Leland Stanford Junior University (Palo Alto, CA) 2027-10-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
AstraZeneca
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.